|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 363.25 CHF | +12.15% |
|
0.00% | +11.30% |
| 07-27 | Sika raises annual sales-growth outlook after strong first-half performance | RE |
| 07-27 | IDEAYA Biosciences Advances IDE892 Into Phase 1/2 Monotherapy Expansion | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 1,276.96 | +4.61% | 26 | ||||||
| 270.59 | +1.45% | 22 | ||||||
| 268.68 | +2.08% | 28 | ||||||
| 153.99 | -3.49% | 21 | ||||||
| 211.36 | +22.78% | 22 | ||||||
| 317.2 | -5.43% | 24 | ||||||
| 357.03 | -9.17% | 29 | ||||||
| 157.15 | +17% | 27 | ||||||
| 28.75 | +13.86% | 26 | ||||||
| 62.96 | -1.01% | 24 | ||||||
| 554.91 | +13.16% | 23 | ||||||
| 96.14 | +21.11% | 23 | ||||||
| 21.39 | +5.42% | 20 | ||||||
| 9,686.67 | +38.4% | 15 | ||||||
| 6,318.94 | +10.01% | 16 | ||||||
| 54.92 | +16.77% | 18 | ||||||
| 80.33 | +50.75% | 15 | ||||||
| 4.142 | +8.75% | 17 | ||||||
| Average | 1,106.78 | +11.50% | 22 | ||||||
| Weighted average by Cap. | 727.98 | +5.90% | 24 |
- Stock Market
- Stocks
- ROP Stock
- 0QOK Stock
- Sector Roche Holding AG
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
